Skip to main content

Master of Public Health

Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.

AUTHORS

Penson DF , Armstrong AJ , Concepcion R , Agarwal N , Olsson C , Karsh L , Dunshee C , Wang F , Wu K , Krivoshik A , Phung , Higano CS , . Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 1 25; ().
  • NIHMSID: 8309333

ABSTRACT

Enzalutamide, a potent oral androgen receptor inhibitor, improves survival in men with metastatic castration-resistant prostate cancer (CRPC) before and after chemotherapy. Bicalutamide, a nonsteroidal antiandrogen, is widely used to treat men with nonmetastatic or metastatic CRPC. The efficacy and safety of these drugs were compared in this randomized, double-blind, phase II study of men with CRPC.

Enzalutamide, a potent oral androgen receptor inhibitor, improves survival in men with metastatic castration-resistant prostate cancer (CRPC) before and after chemotherapy. Bicalutamide, a nonsteroidal antiandrogen, is widely used to treat men with nonmetastatic or metastatic CRPC. The efficacy and safety of these drugs were compared in this randomized, double-blind, phase II study of men with CRPC.

Tags: